These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 25093491)

  • 61. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
    Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
    Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.
    Li L; Zhao S; Liu Z; Zhang N; Pang S; Liu J; Liu C; Fan Y
    Cell Death Dis; 2021 Feb; 12(2):220. PubMed ID: 33637706
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway.
    Bohinc B; Michelotti G; Diehl AM
    Thyroid; 2013 Sep; 23(9):1119-26. PubMed ID: 23410206
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
    Karam JA; Zhang XY; Tamboli P; Margulis V; Wang H; Abel EJ; Culp SH; Wood CG
    Eur Urol; 2011 Apr; 59(4):619-28. PubMed ID: 21167632
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
    Maute L; Grünwald V; Weikert S; Kube U; Gauler T; Kahl C; Burkholder I; Bergmann L
    J Cancer Res Clin Oncol; 2014 May; 140(5):823-7. PubMed ID: 24556802
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures.
    Cohen JR; Resnick DZ; Niewiadomski P; Dong H; Liau LM; Waschek JA
    BMC Cancer; 2010 Dec; 10():676. PubMed ID: 21143927
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
    Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
    J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
    Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
    Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
    Motzer RJ; Barrios CH; Kim TM; Falcon S; Cosgriff T; Harker WG; Srimuninnimit V; Pittman K; Sabbatini R; Rha SY; Flaig TW; Page R; Bavbek S; Beck JT; Patel P; Cheung FY; Yadav S; Schiff EM; Wang X; Niolat J; Sellami D; Anak O; Knox JJ
    J Clin Oncol; 2014 Sep; 32(25):2765-72. PubMed ID: 25049330
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
    Beck J; Bellmunt J; Escudier B
    Med Oncol; 2011 Dec; 28(4):1379-83. PubMed ID: 20593250
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
    Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C
    Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth.
    Ruan H; Luo H; Wang J; Ji X; Zhang Z; Wu J; Zhang X; Wu X
    Biochim Biophys Acta; 2016 Sep; 1860(9):1961-72. PubMed ID: 27316313
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hedgehog signaling drives cellular survival in human colon carcinoma cells.
    Mazumdar T; DeVecchio J; Shi T; Jones J; Agyeman A; Houghton JA
    Cancer Res; 2011 Feb; 71(3):1092-102. PubMed ID: 21135115
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
    Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
    Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
    Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
    J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
    Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
    Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of inhibition of hedgehog signaling on cell growth and migration of uveal melanoma cells.
    Duan F; Lin M; Li C; Ding X; Qian G; Zhang H; Ge S; Fan X; Li J
    Cancer Biol Ther; 2014 May; 15(5):544-59. PubMed ID: 24553082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.